Pushing for change with passion

Innovation will be Novartis' priority in 2016, its chief says

Joseph Jimenez, CEO of the Swiss pharmaceutical giant Novartis International AG, is a titan in the industry. A few years ago, he was named one of the 25 most influential people in biopharma.

Since taking over as CEO in 2010, he has consistently stressed the need for innovation and a new strategy as a "patent cliff" threatened major drugmakers.